Rishil J. Kathawala

Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)

Wen Deng, Chun-ling Dai, JUN-JIANG CHEN et al. · Oncology Reports · 2013 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1

Yi‐Jun Wang, Rishil J. Kathawala, Yunkai Zhang et al. · Biochemical Pharmacology · 2014 · 56 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

<i>In vitro</i>, <i>in vivo</i> and <i>ex vivo</i> characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter <scp>MRP1</scp>

Hui Zhang, Atish Patel, Shaolin Ma et al. · British Journal of Pharmacology · 2014 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR

Nagaraju Anreddy, Atish Patel, Kamlesh Sodani et al. · Acta Pharmaceutica Sinica B · 2014 · 52 citations · Full text

Medicine, Oncology, Pharmacology +14

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2

De‐Shen Wang, Atish Patel, Suneet Shukla et al. · Oncotarget · 2014 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16